← Eichor
Study identifier: NCT06525636 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

A First-in-human Study of KK8123 in Adults With X-linked Hypophosphatemia

Condition: X-linked Hypophosphatemia  ·  Sponsor: Kyowa Kirin Co., Ltd.

PhasePhase 1/Phase 2
Planned participants24
Who can joinAll sexes, 18 Years to 65 Years
Healthy volunteersNo

About this study

A first-in-human study of KK8123 in adults with X-linked hypophosphatemia.

This description comes directly from the study's public registry record.

Talk to the study team

Kyowa Kirin  ·  609-919-1100  ·  KKD.Clintrial.82@kyowakirin.com

Always discuss trial participation with your own doctor first.

Locations (9)

University of California - San FranciscoSan Francisco, California, United StatesRecruiting
Yale Center for XLH/ Yale University School of MedicineNew Haven, Connecticut, United StatesRecruiting
Indiana University School of Medicine University HospitalIndianapolis, Indiana, United StatesRecruiting
Mayo ClinicRochester, Minnesota, United StatesNot Yet Recruiting
Vanderbilt University Medical CenterNashville, Tennessee, United StatesRecruiting
Hoptial BictreLe Kremlin-Bicêtre, Paris, FranceRecruiting
Institute of Osteology and Biomechanics (IOBM)Hamburg, GermanyRecruiting
Universitaetsklinikum WurzburgWürzburg, GermanyRecruiting
Hospital Universitario La PazMadrid, SpainRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06525636